FDA Commissioner Marty Makary was behind a “short-lived request” last week to reject a rare disease drug application from KalVista (KALV), multiple agency sources told Senior Biopharma Correspondent Andrew Dunn of Endpoints News.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- KalVista trading resumes
- KalVista trading halted, volatility trading pause
- Positive Outlook on KalVista Pharmaceuticals’ Sebetralstat Approval Despite FDA Decision Delay
- Optimistic Buy Rating for KalVista Pharmaceuticals Amid FDA Delay
- KalVista says FDA will not meet PDUFA goal date for Sebetralstat NDA